Clinical symptoms of acquired hemophilia A in elderly patients can vary widely, a series of six case reports reveals. Also, these patients should be managed individually in order to achieve the best care and outcome, researchers suggest. The cases were described in the study “Management of…

Changes are happening in the bleeding disorder community like I never imagined. New product after new product has hit the marketplace, each one claiming to be the best available. They all have great claims, with less infusing being the No. 1 draw. But how do you know if…

One ordinary evening, while a dear cousin and I relaxed in my living room, we delved into a profound conversation about purpose. We pondered why some people who struggle with mental health would cling to altruistic pursuits despite financial challenges they may have, especially since those challenges could create more…

Daratumumab — a cancer therapy marketed as Darzalex — can reduce levels of factor VIII (FVIII) inhibitors in people with hemophilia type A, researchers say. Their findings were published in a letter to the editor, titled “Daratumumab rapidly reduces high‐titre factor VIII inhibitors in…

Living with hemophilia involves more than managing physical symptoms. It comes with mental and emotional challenges, too. My husband, Jared, who has severe hemophilia B and epilepsy, has spent much of his life feeling the need to prove himself. From childhood to adulthood, this drive for validation shaped…

My wife, Cazandra, and I enjoy speaking on topics critical to the bleeding disorders community, as both of our adult sons live with hemophilia. A few weeks ago, we had the chance to lead a seminar called “Telling Our Stories” at the National Bleeding Disorders Foundation’s (NBDF) annual…

Prophylactic, or preventive, treatment with Alhemo (concizumab) is associated with better quality of life and a lower treatment burden for people with hemophilia A or B without inhibitors, according to patient-reported data from a Phase 3 trial. The ongoing study, called explorer8 (NCT04082429), is investigating the…

Dimension Therapeutics may soon become a wholly owned subsidiary of Regenxbio, following the terms of an agreement between the two companies. The merger agreement, if finalized, will add Dimension’s investigational drug candidates being developed to Regenxbio’s pipeline, including DTX201 for the treatment of hemophilia A. DTX201 was being developed…

A gene therapy that can treat patients with severe hemophilia A is likely to be more cost-effective over the long term than reliance on prophylactic (preventive) therapy using factor VII (FVIII), a model-based analysis of the two treatment approaches reports. The study, “Gene therapy in hemophilia A: a cost-effectiveness…

The Hemophilia Federation of America (HFA) is seeking a variety of historical artifacts and records to add to its archival project in honor of its upcoming 25th year of helping the bleeding disorders community. The nonprofit is collecting vintage medical equipment, supplies, rally posters, newsletters, documents, personal journals, diaries, and…